252
Views
1
CrossRef citations to date
0
Altmetric
Articles

CYP3A4*22 and CYP3A5*3 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome

ORCID Icon, , , , , & show all
Pages 73-76 | Received 06 Jan 2022, Accepted 08 Apr 2022, Published online: 26 Apr 2022

References

  • Sachdeva A, Choudhary M, Chandra M. Alcohol withdrawal syndrome: benzodiazepines and beyond. J Clin Diagn Res. 2015;9(9):VE01–VE07.
  • Pergolizzi JV, Jr, LeQuang JA, Raffa RB. Benzodiazepines: thinking outside the black box. J Clin Pharm Ther. 2021;46(3):554–559.
  • Amato L, Minozzi S, Vecchi S, et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2010;3;CD005063.
  • Langlois H, Cormier M, Villeneuve E, et al. Benzodiazepine resistant alcohol withdrawal: what is the clinician's preferred definition? CJEM. 2020;22(2):165–169.
  • Hack JB, Hoffman RS, Nelson LS. Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early? J Med Toxicol. 2006;2(2):55–60.
  • Benedict NJ, Wong A, Cassidy E, et al. Predictors of resistant alcohol withdrawal (RAW): a retrospective case-control study. Drug Alcohol Depend. 2018;192:303–308.
  • Westlind-Johnsson A, Malmebo S, Johansson A, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003;31(6):755–761.
  • Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the "missing heritability" problem. Front Genet. 2013;4:12.
  • Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688–700.
  • García-Martín E, Martínez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71(3):196–204.
  • Lamba J, Hebert JM, Schuetz EG, et al. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012;22(7):555–558.
  • Skryabin VY, Zastrozhin MS, Grishina EA, et al. Using the CYP3A activity evaluation to predict the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. J Pharm Pract. 2021;24:897190021997000.
  • Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res. 2005;11(20):7398–7404.
  • Kranzler HR, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des. 2010;16(19):2141–2148.
  • Nuss MA, Elnicki DM, Dunsworth TS, et al. Utilizing CIWA-Ar to assess use of benzodiazepines in patients vulnerable to alcohol withdrawal syndrome. W V Med J. 2004;100(1):21–25.
  • Carcaño-Calderón L, Ramos-Peñafiel CO, Salcedo-Roldán M, et al. Factor analysis and correlation between CIWA-Ar protocol and biochemical-hematic profile in patients with alcohol withdrawal syndrome. Rev Med Hosp Gen Méx. 2015;78(4):155–161.
  • Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.